Methylenedioxybenzylamphetamine

(Redirected from MDBZ)

Methylenedioxybenzylamphetamine, abbreviated MDBZ, and systematically named 3,4-methylenedioxy-N-benzylamphetamine, is a psychedelic drug. It is the N-benzyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.

Methylenedioxybenzyl­amphetamine
Names
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-benzylpropan-2-amine
Identifiers
3D model (JSmol)
ChemSpider
UNII
  • InChI=1S/C17H19NO2/c1-13(18-11-14-5-3-2-4-6-14)9-15-7-8-16-17(10-15)20-12-19-16/h2-8,10,13,18H,9,11-12H2,1H3
    Key: DWLUHTUYTBWOLO-UHFFFAOYSA-N
  • C1=C3C(=CC=C1CC(C)NCC2=CC=CC=C2)OCO3
Properties
C17H19NO2
Molar mass 269.343 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ.[1]

Legality

edit

United Kingdom

edit

MDBZ is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]

See also

edit

References

edit
  1. ^ "House of Commons Hansard Written Answers for 23 July 1996 (pt 10)". Parliamentary Debates (Hansard). 23 July 1996.
  2. ^ "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.
edit